First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be pr ...

Core Insights - Deucrictibant shows a 93% reduction in HAE attack rates and maintains efficacy over long-term use, positioning it as a potential preferred therapy for HAE management [1][2][4] - The median onset of symptom relief for on-demand treatment is approximately 1.1 hours, with a high percentage of attacks resolving within 24 hours [1][5] - The safety and tolerability profile of deucrictibant has been confirmed through multiple studies, indicating no new safety signals [6][4] Prophylactic Program - The CHAPTER-1 study demonstrated that 90% of participants receiving deucrictibant reported well-controlled HAE at week 12 compared to 37.5% in the placebo group [3] - Participants treated with deucrictibant reported higher satisfaction regarding effectiveness and global satisfaction compared to those on placebo [3] On-Demand Program - In the RAPIDe-2 study, the median time to onset of symptom relief was 1.1 hours, with 98.5% of attacks achieving relief within 12 hours [5] - The median time to complete attack resolution was 11.5 hours, with 85.8% of attacks resolving completely within 24 hours [5] - A propensity-score matched analysis indicated that outcomes for attacks treated with deucrictibant were more favorable than those treated with standard care [5] Safety - Cardiovascular safety assessments of deucrictibant showed no adverse effects on cardiovascular parameters in both nonclinical and clinical studies [6] About Deucrictibant - Deucrictibant is a novel oral bradykinin B2 receptor antagonist designed to prevent and treat HAE attacks, with both extended-release and immediate-release formulations under development [8] About Pharvaris - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for HAE, with ongoing Phase 3 studies planned for both prophylactic and on-demand treatment [9]

Haemonetics (HAE) has been on a downward spiral lately with significant selling pressure. After declining 15.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock ...

Company Overview - Haemonetics Corporation has announced the full market release of its VASCADE MVP XL, a mid-bore venous closure system, now available to U.S. hospitals as part of its VASCADE portfolio [1][2] - The VASCADE MVP XL system is designed for procedures requiring 10-12F sheaths (up to 15F in outer diameter) and utilizes 58% more collagen and a larger disc compared to the previous VASCADE MVP system [3][6] - The system is intended for various procedures, including cryoablation, Pulsed Field Ablation (PFA), and Left Atrial Appendage Closure (LAAC) [3] Market Position and Prospects - The company is well-positioned to expand the indications for the VASCADE MVP XL system, targeting larger access points, which aligns with the growing vascular closure solutions market [2] - The global vascular closure devices market was valued at $1.75 billion in 2023 and is projected to reach $3.30 billion by 2033, with a CAGR of 6.55% [7] Recent Developments - Following positive feedback during a limited market release, Haemonetics aims to make the VASCADE MVP XL available to all U.S. hospitals promptly [5] - The company received CE Mark certification for the SavvyWire guidewire in July 2024, marking a significant step in its international expansion strategy [8] - In April 2024, Haemonetics acquired Attune Medical, expected to increase revenues by $35 million [10] Financial Performance - Year-to-date, Haemonetics shares have decreased by 13.5%, contrasting with the industry's growth of 5.8% [11]

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold player ...

BOSTON, Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable c ...

Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of $1.02 in the first quarter of fiscal 2025, down 2.9% year over year. The bottom line missed the Zacks Consensus Estimate by 0.9%. On a GAAP basis, the EPS was 74 cents compared with 80 cents in the prior-year quarter. Total Revenues Revenues increased 8% (up 2.8% on an organic basis) to $336.2 million in the first quarter of fiscal 2025. The top line beat the Zacks Consensus Estimate by 0.1%. Segments in Detail At Plasma, revenues ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a ...

Core Viewpoint - Haemonetics (HAE) has experienced significant selling pressure, resulting in a 14.6% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [1]. Group 1: Stock Performance and Indicators - HAE shares are currently in oversold territory, with a Relative Strength Index (RSI) reading of 28.12, suggesting a possible reversal in trend [3]. - The stock's heavy selling appears to be exhausting, indicating a potential return to equilibrium in supply and demand [3]. Group 2: Earnings Estimates and Analyst Sentiment - There has been a consensus among sell-side analysts to raise earnings estimates for HAE, resulting in a 0.2% increase in the consensus EPS estimate over the last 30 days [3]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [3]. - HAE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [3].

Core Viewpoint - Haemonetics reported quarterly earnings of $1.02 per share, slightly missing the Zacks Consensus Estimate of $1.03 per share, and down from $1.05 per share a year ago [1][2] Financial Performance - The company posted revenues of $336.17 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 0.09% and up from $311.33 million year-over-year [3] - Over the last four quarters, Haemonetics has exceeded consensus revenue estimates three times [3] Stock Performance and Outlook - Haemonetics shares have increased by approximately 0.3% since the beginning of the year, while the S&P 500 has gained 9% [4] - The current consensus EPS estimate for the upcoming quarter is $1.11 on revenues of $346.75 million, and for the current fiscal year, it is $4.58 on revenues of $1.39 billion [8] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Haemonetics' stock performance [6][7]